

## **Supplemental Figures and Figure Legends**

**Fig. S1** Effects of GDF-15 on APs and membrane properties of DRG neurons. **A.** The AP firing response to a 100-pA depolarizing current pulse in control and GDF-15-treated DRG neurons. **B.** Summary data showing the inhibitory effects of GDF-15 on the firing rate in DRG neurons (\**P* <0.05, Student's *t*-test). **C.** The AP firing response to a ramp current stimulation (0–100 pA, 500 ms) in control and GDF-15-treated DRG neurons. **D and E.** GDF-15 prolongs the latency to the first AP (**D**) and reduces the number of APs (**E**) (\**P* <0.05, Student's *t*-test). **F–I.** The effects of GDF-15 on resting membrane potential (**F**), AP amplitude, AP half-width, and after-hyperpolarization potential (AHP) (Student's *t*-test).



**Fig. S2** Effects of GDF-15 on Nav1.8 channels of DRG neurons from CFA-arthritic rats. **A–C.** Intraankle articular injection of CFA increases the circumference of the ankle joint (**A**), and produces thermal hyperalgesia (**B**) and mechanical allodynia (**C**) (\*\*P <0.01, two-way RM ANOVA). **D and E.** Intraplantar injection of GDF-15 antibody (GDF-15 Ab, 25 µg) to block the endogenous GDF-15

results in a decreased mechanical (**D**) and thermal (**E**) response threshold (\*P < 0.05, \*\*P < 0.01, twoway RM ANOVA). **F.** Examples showing the Nav1.8 currents of DRG neurons from sham and CFAarthritic rats. **G.** GDF-15 reduces the CFA-induced increase in Nav1.8 current density on day 5 after CFA (\*P < 0.05, one-way ANOVA). **H and I.** CFA-inflammation induces a left-shifted activation curve of Nav 1.8 channels (**H**), but does not change the steady-state inactivation curve (**I**). GDF-15 (1.2 nmol/L) does not affect the steady-state activation curves of Nav1.8 channels (**H**), but causes a left-shift toward hyperpolarizing potential of the steady-state inactivation curve (**I**).